|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Oral immunoglobulin for the treatment of rotavirus diarrhoea in low birth weight infantsMohan P, Haque KN
Bookmark this:
     more ...
SummaryOral immunoglobulin for the treatment of rotavirus diarrhoea in low birth weight infantsRotavirus infection can cause significant problems including diarrhoea in the newborn. This is particularly true in babies weighing less than 2500 g (low birthweight infants). Rotavirus infection is becoming more common in newborn babies and can spread from one baby to another in the neonatal unit. Administration of antibodies against rotavirus to babies may be one of the methods to treat this infection and to prevent the spread of infection in the neonatal unit. In this review, we did not identify any trial that used antibodies to treat rotavirus infection. More research is needed to address these issues.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
January 20. 2003 AbstractBackgroundRotavirus infection is the most common neonatal nosocomial viral infection. It is a major health problem worldwide. Epidemics with the newer P(6)G9 strains have been reported in neonatal units globally. These strains can cause severe symptoms in most infected infants. Infection control measures become necessary and the utilization of hospital resources increase. Local mucosal immunity in the intestine to rotavirus is important in the resolution of infection and protection against subsequent infections. Boosting local immunity by oral administration of anti-rotaviral immunoglobulin preparations might be a useful strategy in treating rotaviral infections, especially in low birth weight babies. ObjectivesTo determine the effectiveness and safety of oral immunoglobulin preparations for the treatment of rotavirus diarrhoea in hospitalized low birthweight infants (birth weight less than 2500 g) Search strategyElectronic databases including The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2004), MEDLINE, EMBASE and CINAHL, Biological Abstracts (BIOSIS) were searched by the strategy outlined in the protocol. Science Citation Index search for all articles that referenced Barnes 1982 were searched. The proceedings of the Pediatric Academic Societies, which were published in the journal Pediatric Research from 1991 and 'Abstracts Online' were searched. Authors prominent in the field were contacted for any unpublished articles and more information on published articles was sought. Reference lists of identified clinical trials and personal files were also reviewed. The above search was updated in April 2007. Selection criteriaThe criteria used to select studies for inclusion were: Data collection and analysisThe two reviewers were to independently abstract data from eligible trials. No data were available for analysis. Main resultsNo eligible randomized controlled trials were found. Authors' conclusionsNo randomized controlled trials that assessed the effectiveness or safety of oral immunoglobulin preparations for the treatment of rotavirus diarrhoea in hospitalized low birthweight infants were found. Clinical trials that address the issue of oral immunoglobulin treatment of rotavirus infection are needed. |